Clinical Trial Detail

NCT ID NCT02493361
Title Trial of pIL-12/MK-3475 in Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alain Algazi
Indications

melanoma

Therapies

Pembrolizumab

IL-12 gene

Age Groups: adult

No variant requirements are available.